Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, including men, postmenopausal women, and premenopausal or perimenopausal women (premenopausal or perimenopausal women must be willing to receive hormone-suppressing injections called LHRH agonists during the study)
- People whose breast cancer has been confirmed by a pathology test to be hormone receptor (HR)-positive, and whose cancer has come back or spread to other parts of the body in a way that cannot be fully treated with surgery or radiation
- People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard medical scoring system called ECOG (scores 0–2, meaning fully active to capable of limited self-care)
- Women of childbearing age whose pregnancy test (done within 28 days before joining) comes back negative, and all participants who are willing to use a highly effective form of contraception throughout the study and for one year after the last dose
- Women who are not currently pregnant or breastfeeding
- People who are not currently taking part in another clinical trial at the same time
- People who have read and signed an informed consent form and are willing and able to attend scheduled visits, follow the treatment plan, and complete required tests and procedures
Who may not be able to join:
- People with serious or uncontrolled health conditions, such as uncontrolled high blood pressure, active bleeding problems, active infections (including hepatitis B, hepatitis C, or HIV), or significant damage to bone marrow, liver, or kidney function — where the treating doctor believes the risks would outweigh the benefits
- People who are still experiencing significant side effects (grade 3 or higher on a standard medical scale) from a previous cancer treatment at the time this new treatment would begin
- People with a known allergy or sensitivity to the study drug (dalpiciclib), its inactive ingredients, or to other drugs with a similar chemical structure
- People whom the trial investigator considers unsuitable for the study for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Cuizhi Geng Cuizhi Geng, archiater, Hebei Medical University Fourth Hospital
Phone: +8613503216325
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
PFS; AE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.